OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies focused on the research, development and commercialization of materials and devices engineered at the nanoscale (1–100 nanometers). By investing in these firms, shareholders gain exposure to potential breakthroughs in sectors such as electronics, medicine and advanced materials. While offering significant long-term growth prospects, nanotechnology stocks can also exhibit elevated volatility and risk due to heavy R&D costs and evolving regulatory landscapes. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
NASDAQ OSIS traded up $8.57 during mid-day trading on Wednesday, reaching $240.17. The stock had a trading volume of 195,688 shares, compared to its average volume of 197,004. OSI Systems has a 1 year low of $129.18 and a 1 year high of $241.59. The company has a fifty day moving average price of $210.60 and a 200 day moving average price of $194.66. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. The stock has a market cap of $4.03 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NVEC traded down $0.80 during mid-day trading on Wednesday, reaching $72.69. 35,384 shares of the company traded hands, compared to its average volume of 26,601. NVE has a 52-week low of $51.50 and a 52-week high of $89.98. The stock has a market capitalization of $351.60 million, a P/E ratio of 23.52 and a beta of 1.15. The company's fifty day moving average price is $64.51 and its 200-day moving average price is $70.65.
Read Our Latest Research Report on NVEC
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of CLNN stock traded down $0.10 during mid-day trading on Wednesday, hitting $4.16. The company had a trading volume of 47,801 shares, compared to its average volume of 88,002. The company has a market capitalization of $37.38 million, a P/E ratio of -0.79 and a beta of 0.49. Clene has a 52-week low of $2.28 and a 52-week high of $8.99. The stock's 50 day moving average price is $3.02 and its 200-day moving average price is $3.99.
Read Our Latest Research Report on CLNN
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of NASDAQ:BDRX traded down $0.01 during trading on Wednesday, reaching $1.14. The company's stock had a trading volume of 140,357 shares, compared to its average volume of 850,960. Biodexa Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $41.50. The firm's 50 day simple moving average is $1.36 and its two-hundred day simple moving average is $2.95.
Read Our Latest Research Report on BDRX
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Shares of Virpax Pharmaceuticals stock traded up $0.01 during trading on Wednesday, hitting $0.27. The stock had a trading volume of 59,025 shares, compared to its average volume of 201,486. Virpax Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $84.75. The firm's fifty day simple moving average is $0.25 and its 200-day simple moving average is $4.67.
Read Our Latest Research Report on VRPX
Featured Stories
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
